Loading the section
Closing prices for 09 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Protagonist Therapeutics, Inc. trades on Nasdaq under the ticker PTGX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks PTGX has traded between 65.56 $ and 160.81 $. As of 09 October 2026 the price stood 82.07 % of the way from the 52-week low to the high.
Over one year PTGX shares rose 120.11 %; over six months they rose 45.45 %. Volatility over 90 days is 41.38 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 122, above the sector median of 3.9. Price to book is 13.8, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 139.92 | 146.30 | 138.95 | 143.73 | 761,527 |
| 08 October 2026 | 139.57 | 142.18 | 137.99 | 139.91 | 1M |
| 07 October 2026 | 137.34 | 144.10 | 137.25 | 140.92 | 927,300 |
| 06 October 2026 | 140.34 | 141.00 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Protagonist Therapeutics, Inc. (PTGX) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 46.0m $, net income was -130.1m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160, US
Protagonist Therapeutics, Inc. reported revenue of 74M $ and a net loss of 115M $ over the last four quarters. Net margin is −154.88 %. Revenue changed by −64.36 % year over year. Earnings per share are −1.81 $. Market capitalisation is 9.0B $.
PTGX has a return on equity of −17.50 %, above the sector median of −41.68 %. Return on assets is −16.45 %, above the sector median of −32.11 %. Operating margin is −192.36 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 136.09 |
| 138.69 |
| 635,700 |
| 05 October 2026 | 139.96 | 142.51 | 138.08 | 140.63 | 1M |
| 02 October 2026 | 140.99 | 141.71 | 138.37 | 140.06 | 760,300 |
| 01 October 2026 | 139.23 | 143.68 | 138.37 | 139.19 | 886,200 |
| 30 September 2026 | 141.60 | 143.74 | 140.44 | 140.89 | 787,700 |
| 29 September 2026 | 143.45 | 144.09 | 138.88 | 140.97 | 508,000 |
| 28 September 2026 | 142.21 | 143.69 | 140.24 | 142.44 | 925,500 |
| 25 September 2026 | 141.81 | 143.45 | 138.23 | 141.86 | 809,200 |
| 24 September 2026 | 138.76 | 140.80 | 134.10 | 137.34 | 989,200 |
| 23 September 2026 | 144.27 | 145.28 | 137.88 | 138.70 | 513,200 |
| 22 September 2026 | 144.64 | 147.71 | 144.50 | 145.07 | 806,200 |
| 21 September 2026 | 143.22 | 145.37 | 141.09 | 144.98 | 822,200 |
| 18 September 2026 | 143.09 | 144.58 | 140.44 | 143.00 | 2M |
| 17 September 2026 | 144.39 | 146.50 | 142.31 | 143.70 | 558,900 |
| 16 September 2026 | 144.19 | 146.19 | 140.88 | 142.84 | 507,000 |
| 15 September 2026 | 147.48 | 147.99 | 142.00 | 143.40 | 637,500 |
| 14 September 2026 | 150.23 | 151.24 | 146.83 | 147.78 | 608,000 |